'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target

  • Emergent BioSolutions Inc's EBS Q3 sales fell 27% Y/Y to $240 million, missing the consensus of $268.30 million.
  • Revenues from CDMO services decreased $76.4 million, largely due to lower combined revenues of $59.1 million from AstraZeneca Plc AZN and Johnson & Johnson's JNJ Janssen, reflecting the impact of reduced production activities for the companies' COVID-19 vaccines. 
  • The company reported an adjusted EPS loss of $(1.27), compared to $(0.36) a year ago and missing the consensus of $(0.06).
  • Related: FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility.
  • Guidance: Emergent BioSolutions forecasts FY22 sales of $1.05-$1.10 billion, down from $1.15-$1.25 billion expected earlier, compared to the consensus of $1.20 billion.
  • Post 3Q22 results, Cantor Fitzgerald, reiterated its Neutral rating and revised the price target to $23 from $33
  • Analyst Reaction: The analyst writes that while on the surface, Emergent BioSolutions' stock looks attractive, trading at ~2x 2022E sales on an EV/revenue basis, there remain multiple overhangs that the company will need to work through. 
  • Narcan continues to do well, but that is a genericized market. The company's medical countermeasures business will remain an integral part but with several overhangs, such as the likelihood and timing of the next option getting exercised.
  • Price Action: EBS shares are down 29.80% at $13.86 on the last check Wednesday.
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!